Cargando…

TAK-242, a small-molecule inhibitor of Toll-like receptor 4 signalling, unveils similarities and differences in lipopolysaccharide- and lipidinduced inflammation and insulin resistance in muscle cells

Emerging evidence suggests that TLR (Toll-like receptor) 4 and downstream pathways [MAPKs (mitogen-activated protein kinases) and NF-κB (nuclear factor κB)] play an important role in the pathogenesis of insulin resistance. LPS (lipopolysaccharide) and saturated NEFA (non-esterified fatty acids) acti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hussey, Sophie E., Liang, Hanyu, Costford, Sheila R., Klip, Amira, DeFronzo, Ralph A., Sanchez-Avila, Alicia, Ely, Brian, Musi, Nicolas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Portland Press Ltd. 2012
Materias:	Original Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3522475/ https://www.ncbi.nlm.nih.gov/pubmed/23050932 http://dx.doi.org/10.1042/BSR20120098

Ejemplares similares

Selective inhibition of Toll-like receptor 4 signaling by the small molecule TAK-242
por: Kawamoto, T, et al.
Publicado: (2006)

The Toll-like receptor 4 antagonist TAK-242 protects against chronic pancreatitis in rats
por: Pan, Long-Fei, et al.
Publicado: (2017)

Effect of Lipopolysaccharide on Inflammation and Insulin Action in Human Muscle
por: Liang, Hanyu, et al.
Publicado: (2013)

Toll-like 4 receptor inhibitor TAK-242 decreases neuroinflammation in rat brain frontal cortex after stress
por: Gárate, Iciar, et al.
Publicado: (2014)

TAK-242, a Toll-Like Receptor 4 Antagonist, Protects against Aldosterone-Induced Cardiac and Renal Injury
por: Zhang, Yide, et al.
Publicado: (2015)

TAK-242, an antagonist for Toll-like receptor 4, protects against acute cerebral ischemia/reperfusion injury in mice
por: Hua, Fang, et al.
Publicado: (2015)

Pharmacological Inhibition of Toll-Like Receptor-4 Signaling by TAK242 Prevents and Induces Regression of Experimental Organ Fibrosis
por: Bhattacharyya, Swati, et al.
Publicado: (2018)

TAK-242, a toll-like receptor 4 antagonist, against brain injury by alleviates autophagy and inflammation in rats
por: Feng, Yan, et al.
Publicado: (2023)

Investigation of toll-like receptor (TLR) 4 inhibitor TAK-242 as a new potential anti-rheumatoid arthritis drug
por: Samarpita, Snigdha, et al.
Publicado: (2020)

TAK-242 Ameliorates Hepatic Fibrosis by Regulating the Liver-Gut Axis
por: Liu, Sujie, et al.
Publicado: (2022)

TAK-242, a specific inhibitor of Toll-like receptor 4 signalling, prevents endotoxemia-induced skeletal muscle wasting in mice
por: Ono, Yuko, et al.
Publicado: (2020)

Toll-Like Receptor-4 Inhibitor TAK-242 Attenuates Motor Dysfunction and Spinal Cord Pathology in an Amyotrophic Lateral Sclerosis Mouse Model
por: Fellner, Avi, et al.
Publicado: (2017)

TAK-242 ameliorates contact dermatitis exacerbated by IL-36 receptor antagonist deficiency
por: Fukushima, Hidehiko, et al.
Publicado: (2020)

TAK242 suppresses the TLR4 signaling pathway and ameliorates DCD liver IRI in rats
por: Zhong, Xiang, et al.
Publicado: (2019)

TLR4 inhibitor TAK-242 attenuates the adverse neural effects of diet-induced obesity
por: Moser, V. Alexandra, et al.
Publicado: (2018)

TAK-242, a novel Toll-like receptor 4 signal transduction inhibitor, protects mice in Escherichia coli-induced and lipoteichoic acid-induced lethality models
por: Ii, M, et al.
Publicado: (2006)

Targeting Toll-like receptor 4 with CLI-095 (TAK-242) enhances the antimetastatic effect of the estrogen receptor antagonist fulvestrant on non-small cell lung cancer
por: Fan, S., et al.
Publicado: (2020)

Prenatal exposure to TAK242 affects the childhood autism in offspring in animal models of autism spectrum disorder
por: Xu, Xiaoyan, et al.
Publicado: (2017)

TAK-242 ameliorates epileptic symptoms in mice by inhibiting the TLR4/NF-κB signaling pathway
por: Dong, Jibo, et al.
Publicado: (2022)

Sulfonamide Prodrugs with a Two-Stage Release Mechanism for the Efficient Delivery of the TLR4 Antagonist TAK-242
por: Kostyo, Jessica H., et al.
Publicado: (2022)

Male Mice Lacking NLRX1 Are Partially Protected From High-Fat Diet–Induced Hyperglycemia
por: Costford, Sheila R, et al.
Publicado: (2018)

Elevated Toll-Like Receptor 4 Expression and Signaling in Muscle From Insulin-Resistant Subjects
por: Reyna, Sara M., et al.
Publicado: (2008)

Inhibition of intimal hyperplasia in murine aortic allografts by administration of a small-molecule TLR4 inhibitor TAK-242
por: Wu, Chuangyan, et al.
Publicado: (2017)

TAK-242 ameliorates DSS-induced colitis by regulating the gut microbiota and the JAK2/STAT3 signaling pathway
por: Wang, Jiajia, et al.
Publicado: (2020)

Short-Term Exercise Training Improves Insulin Sensitivity but Does Not Inhibit Inflammatory Pathways in Immune Cells from Insulin-Resistant Subjects
por: Reyna, Sara M., et al.
Publicado: (2013)

TAK-242 protects against oxygen-glucose deprivation and reoxygenation-induced injury in brain microvascular endothelial cells and alters the expression pattern of lncRNAs
por: Kong, Li-Yun, et al.
Publicado: (2023)

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009
por: DeFronzo, R. A.
Publicado: (2010)

From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus
por: DeFronzo, Ralph A.
Publicado: (2009)

Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
por: DeFronzo, Ralph A.
Publicado: (2011)

Health Tract, No. 242: Emergencies
Publicado: (1866)

Effects of intravenous AICAR (5-aminoimidazole-4-carboximide riboside) administration on insulin signaling and resistance in premature baboons, Papio sp.
por: Blanco, Cynthia L., et al.
Publicado: (2018)

Skeletal Muscle Insulin Resistance Is the Primary Defect in Type 2 Diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2009)

Visceral fat dominant distribution in male type 2 diabetic patients is closely related to hepatic insulin resistance, irrespective of body type
por: Miyazaki, Yoshinori, et al.
Publicado: (2009)

Is Incretin-Based Therapy Ready for the Care of Hospitalized Patients With Type 2 Diabetes?: The time has come for GLP-1 receptor agonists!
por: Schwartz, Stanley, et al.
Publicado: (2013)

A novel experimental model for human mixed acinar–ductal pancreatic cancer
por: Doiron, Bruno, et al.
Publicado: (2018)

Unveiling the hidden economic toll of biological invasions in the European Union
por: Henry, Morgane, et al.
Publicado: (2023)

Type 2 Diabetes Can Be Prevented With Early Pharmacological Intervention
por: DeFronzo, Ralph A., et al.
Publicado: (2011)

Is It Time to Change the Type 2 Diabetes Treatment Paradigm? Yes! GLP-1 RAs Should Replace Metformin in the Type 2 Diabetes Algorithm
por: Abdul-Ghani, Muhammad, et al.
Publicado: (2017)

Modifying chronic kidney disease progression with the mineralocorticoid receptor antagonist finerenone in patients with type 2 diabetes
por: DeFronzo, Ralph A., et al.
Publicado: (2022)

Altered Insulin Clearance after Gastric Bypass and Sleeve Gastrectomy in the Fasting and Prandial Conditions
por: Salehi, Marzieh, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_kg71omo0cj7ffogjcvuq1g1b13